Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation.
Novoa-Takara
L
L
Dincer
A
A
Kampalath
B
B
Van Tuinen
P
P
Hariharan
S
S
Chang
C
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000032:analysis; D018951:Antigens, CD20 / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D051925:CD79 Antigens; D002454:Cell Differentiation; D002872:Chromosome Deletion; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics; D020031:Epstein-Barr Virus Infections / Q000473:pathology; D006689:Hodgkin Disease / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis; D016030:Kidney Transplantation; D017493:Leukocyte Common Antigens / Q000032:analysis; D016256:Lewis X Antigen / Q000032:analysis; D016393:Lymphoma, B-Cell / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology*; D008232:Lymphoproliferative Disorders / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy / Q000473:pathology; D011947:Receptors, Antigen, B-Cell / Q000032:analysis; D000069283:Rituximab; D016896:Treatment Outcome; D019014:fas Receptor / Q000032:analysis
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D051925:CD79 Antigens; C497881:CD79A protein, human; D017730:Ki-1 Antigen; D016256:Lewis X Antigen; D011947:Receptors, Antigen, B-Cell; D019014:fas Receptor; D000069283:Rituximab; D017493:Leukocyte Common Antigens